Avalo Therapeutics, Inc.
AVTX evidence brief
What we can confirm
- BioSniper Score:
- 5.1 / 10
- Market Cap:
- $876.6M
- Lead Asset:
- abdakibart (Phase 2)
What it means
What to watch
Prepared research question
What matters most for AVTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVTX
Avalo Therapeutics, Inc. (AVTX) is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead candidate abdakibart in Phase 2 for hidradenitis suppurativa.
Key risk: Clinical trial failure
BioSniper Score
Based on 4 of 6 signals
Market Cap
$876.6M
Cash Runway
—
Lead Asset
abdakibart (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for Avalo Therapeutics, Inc..
Avalo Therapeutics, Inc. (AVTX) is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead candidate abdakibart in Phase 2 for hidradenitis suppurativa.
- Cash & equivalents of $85.4M as of 2026-06-30 [sec].
- Net income of -$36.4M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $448.7M as of 2026-06-30 [sec].
- Completed enrollment in Phase 2 LOTUS trial of AVTX-009 (abdakibart) for hidradenitis suppurativa; topline data expected mid-2026 [news · published 2025-11-06].
- Completed an equity offering for net proceeds of $405.0 million in Q2 2026 [sec_mda · as of 2026-08-06].
What works
- Strong cash position of $85.4M as of 2026-06-30, supplemented by a $405M equity offering in Q2 2026, providing extended runway [sec] [sec_mda · as of 2026-08-06].
- Phase 2 LOTUS trial of abdakibart for hidradenitis suppurativa completed enrollment, with topline data expected mid-2026 [news · published 2025-11-06].
- Collaboration with Eli Lilly and Company includes milestone payments up to $70M for development/regulatory and $650M for sales, plus royalties of 5-15% [pipeline].
What to weigh
- Net loss of $36.4M for the period ending 2026-06-30, reflecting significant operating expenses [sec].
- Research and development expense increased by $14.3M for the six months ended June 30, 2026, driven by a $10.0M development milestone for abdakibart and increased CMC costs [sec_mda · as of 2026-08-06].
- The company has incurred significant operating losses since inception and may need additional financing, which could dilute existing stockholders or require relinquishing valuable rights [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Phase 2 LOTUS trial enrollment completed
“Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026”
News · November 6, 2025
Equity offering net proceeds in Q2 2026
“in the second quarter of 2026, we completed an equity offering for net proceeds of $405.0 million”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial failure — Phase 2 LOTUS trial topline data expected mid-2026; negative results could impair pipeline value [news · published 2025-11-06].
- Cash burn rate — Net loss of $36.4M in H1 2026; R&D expenses increased $14.3M, potentially reducing runway [sec] [sec_mda · as of 2026-08-06].
- Dependence on partnerships — Relies on Eli Lilly collaboration; milestone payments and royalties are contingent on development success [pipeline].
- Regulatory and competitive risk — Hidradenitis suppurativa market has multiple competitors (Novartis, AbbVie, Pfizer, etc.) [pipeline].
What to watch
- Topline data from Phase 2 LOTUS trial of abdakibart for hidradenitis suppurativa expected mid-2026 [news · published 2025-11-06].
- Cash runway and burn rate updates in subsequent quarterly filings [sec_mda · as of 2026-08-06].
- Progress on Phase 3 planning for abdakibart and any new partnership or licensing developments [sec_mda · as of 2026-03-23].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run Avalo Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avalo Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.09 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
0 buys · 31 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
97
Total value held
$433.2M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 2,879,481 | $43.0M |
| caligan partners lp | 1,635,023 | $24.4M |
| bvf inc/il | 1,632,845 | $24.4M |
| avoro capital advisors llc | 1,410,000 | $21.1M |
| affinity asset advisors, llc | 1,340,840 | $20.0M |
| nantahala capital management, llc | 1,235,000 | $18.4M |
| ubs group ag | 1,141,980 | $17.0M |
| point72 asset management, l.p. | 916,142 | $13.7M |
| farallon capital management llc | 916,000 | $13.7M |
| rtw investments, lp | 856,962 | $12.8M |
Showing top 10 of 97 institutional holders of Avalo Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 21.5%
- Days to cover
- 7.3
- Shares short
- 5,733,586
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Avalo Therapeutics, Inc.?
Avalo Therapeutics, Inc. (AVTX) is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead candidate abdakibart in Phase 2 for hidradenitis suppurativa.
What is Avalo Therapeutics, Inc.'s lead drug candidate?
Avalo Therapeutics, Inc.'s most advanced tracked candidate is abdakibart (Phase 2) for hidradenitis suppurativa.
Who is the CEO of Avalo Therapeutics, Inc.?
Dr. Garry A. Neil M.D. is the chief executive officer of Avalo Therapeutics, Inc. (AVTX).
Where is Avalo Therapeutics, Inc. headquartered?
Avalo Therapeutics, Inc. (AVTX) is headquartered in Wayne, PA, United States.
What therapeutic areas does Avalo Therapeutics, Inc. focus on?
Avalo Therapeutics, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.